List of Excipients in Branded Drug LORATADINE AND PSEUDOEPHEDRINE SULFATE

Generic Drugs Containing LORATADINE AND PSEUDOEPHEDRINE SULFATE

Company	Ingredient	NDC	Excipient
Major Pharmaceuticals	loratadine and pseudoephedrine sulfate	0904-5833	CALCIUM CARBONATE
Major Pharmaceuticals	loratadine and pseudoephedrine sulfate	0904-5833	CELLULOSE, MICROCRYSTALLINE
Major Pharmaceuticals	loratadine and pseudoephedrine sulfate	0904-5833	FERROSOFERRIC OXIDE
Major Pharmaceuticals	loratadine and pseudoephedrine sulfate	0904-5833	HYDROXYPROPYL CELLULOSE
Major Pharmaceuticals	loratadine and pseudoephedrine sulfate	0904-5833	HYPROMELLOSE
Major Pharmaceuticals	loratadine and pseudoephedrine sulfate	0904-5833	LACTOSE MONOHYDRATE
Major Pharmaceuticals	loratadine and pseudoephedrine sulfate	0904-5833	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in LORATADINE AND PSEUDOEPHEDRINE SULFATE?

# Of NDCs	Excipient
18	CALCIUM CARBONATE
18	CELLULOSE, MICROCRYSTALLINE
4	COLLOIDAL SILICON DIOXIDE
18	FERROSOFERRIC OXIDE
18	HYDROXYPROPYL CELLULOSE
14	HYPROMELLOSE
4	HYPROMELLOSES

Loratadine and Pseudoephedrine Sulfate Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Loratadine and pseudoephedrine sulfate is a mature oral combination used for allergic rhinitis with nasal congestion. The commercial opportunity is concentrated in extended-release tablets, abuse-resistant packaging, pediatric and liquid formats, improved swallowability, and private-label supply rather than new chemical-entity exclusivity. The core technical challenge is combining a low-dose antihistamine with a high-dose, moisture-sensitive sympathomimetic while controlling pseudoephedrine release over 12 or 24 hours.

What is the commercial product profile of loratadine and pseudoephedrine sulfate?

The principal reference products are Claritin-D 12 Hour and Claritin-D 24 Hour, marketed by Bayer Consumer Health in the United States. Their active ingredients are loratadine and pseudoephedrine sulfate.

Product type	Loratadine dose	Pseudoephedrine sulfate dose	Release profile	Common presentation
12-hour tablet	5 mg	120 mg	Extended release	Bilayer or multilayer tablet
24-hour tablet	10 mg	240 mg	Extended release	Controlled-release tablet

Loratadine is a second-generation H1 antihistamine. Pseudoephedrine sulfate is an oral nasal decongestant. The combination targets two symptoms through separate pharmacologic mechanisms: histamine-mediated allergy symptoms and congestion caused by nasal vasodilation.

The product is primarily an OTC drug in the United States under the FDA’s final monograph framework for oral nasal decongestants and antihistamines. The combination remains subject to labeling, dosage, warning, and manufacturing requirements under FDA regulations and applicable OTC monograph conditions.[1-3]

What excipients are used in loratadine and pseudoephedrine sulfate tablets?

Commercial formulations generally use excipients from five functional categories: matrix formers, binders, fillers, disintegrants, lubricants, and coating systems. The precise formula is manufacturer-specific and may change by strength, site, or market.

Representative excipient functions include:

Excipient function	Typical materials	Role in the product
Filler or compression aid	Microcrystalline cellulose, lactose, dibasic calcium phosphate	Provides tablet mass and compressibility
Binder	Povidone, hypromellose, pregelatinized starch	Improves granule and tablet strength
Controlled-release polymer	Hypromellose, ethylcellulose, methacrylate copolymers	Controls pseudoephedrine release
Disintegrant	Crospovidone, sodium starch glycolate, croscarmellose sodium	Supports immediate-release loratadine layer or rapid tablet breakup where required
Lubricant	Magnesium stearate, stearic acid	Reduces punch and die friction
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Protects the tablet and supports product identification
Moisture-control component	High-barrier coating, desiccant packaging, low-moisture excipient system	Limits degradation and physical instability

A formulation should not assume that the excipients used in the reference product are optimal for a new commercial product. The key value is functional performance, not ingredient replication.

What excipient strategy is appropriate for the 12-hour formulation?

The 12-hour product requires approximately 120 mg of pseudoephedrine sulfate per tablet and 5 mg of loratadine. A practical architecture is a bilayer tablet:

1. An immediate-release loratadine layer.
2. A controlled-release pseudoephedrine layer.

This design separates the two actives and reduces the risk that the hydrophilic antihistamine portion will disrupt pseudoephedrine release.

Immediate-release loratadine layer

The loratadine layer can use microcrystalline cellulose, lactose or dibasic calcium phosphate, a superdisintegrant, and a low level of lubricant. The objective is rapid dispersion and consistent dissolution at a low drug load.

Loratadine has limited aqueous solubility. Particle-size control, wetting, granulation method, and surfactant selection can affect dissolution. A formulation developer should control:

• Loratadine particle-size distribution.
• Blend uniformity at the 5 mg dose.
• Dissolution under pH conditions relevant to the gastrointestinal tract.
• Interaction between loratadine and acidic or alkaline excipients.
• Sensitivity to over-lubrication.

Controlled-release pseudoephedrine layer

Hydrophilic matrix technology is usually the lowest-complexity platform. Hypromellose grades with different viscosities can be screened to establish the release rate. Ethylcellulose or polymer-coated multiparticulates can provide greater control but increase manufacturing complexity.

For a 12-hour product, a matrix formulation may use:

• A high-viscosity hypromellose grade as the primary release-controlling polymer.
• Microcrystalline cellulose or dibasic calcium phosphate as a diluent.
• Povidone as a binder.
• Colloidal silicon dioxide for flow.
• Magnesium stearate at a controlled concentration.

The formulation must resist rapid release when exposed to alcohol, altered pH, or mechanical damage. FDA’s modified-release guidance places emphasis on dissolution performance, dose dumping, and food effects.[4]

What excipient strategy is appropriate for the 24-hour formulation?

The 24-hour formulation contains 240 mg of pseudoephedrine sulfate and requires a stronger release-control system than the 12-hour product. The principal options are:

Hydrophilic matrix tablet

A high-viscosity hypromellose matrix can be engineered to release pseudoephedrine over approximately 24 hours. This approach has a low unit cost and is well suited to high-volume OTC manufacturing.

The main risks are:

• Early release caused by tablet porosity or inadequate polymer hydration.
• Late-release retention caused by an overly dense gel layer.
• Food-related changes in gastrointestinal transit or hydration.
• Alcohol-induced release acceleration.
• Tablet size and swallowability.

Coated multiparticulate system

Pseudoephedrine-containing pellets or granules can be coated with ethylcellulose or a methacrylate polymer and compressed into a tablet or filled into a capsule. This architecture provides more independent control of release fractions.

It also creates higher costs related to:

• Pellet manufacture.
• Coating uniformity.
• Residual solvent or aqueous coating control.
• Compression damage to coated particles.
• Scale-up and in-process testing.

Osmotic or membrane-controlled system

An osmotic system can deliver a more predictable release profile but is generally less attractive for a mature OTC product because of tooling, process, and intellectual-property costs. It may be commercially relevant where a sponsor seeks a differentiated once-daily profile, a narrower food-effect window, or a premium product position.

How should the two active ingredients be physically separated?

Physical separation is often the most important formulation decision. Loratadine and pseudoephedrine have different dose levels, solubility characteristics, and desired release behaviors.

Architecture	Commercial advantage	Main risk
Bilayer tablet	Separates release functions and supports conventional compression	Layer adhesion, weight variation, and higher tooling complexity
Monolithic matrix	Lowest manufacturing complexity	More difficult to optimize independent release of both actives
Coated multiparticulates	Strong control of release and dose flexibility	Higher cost and more complex quality testing
Capsule-in-capsule or pellet capsule	Flexible release design	Less familiar OTC presentation and higher packaging cost
Dual-layer osmotic system	Potentially differentiated 24-hour performance	High development and manufacturing burden

A bilayer tablet is generally the strongest balance between performance and cost for a generic, private-label, or line-extension product.

What manufacturing and excipient barriers affect commercial entry?

The main barriers are formulation reproducibility, controlled-release dissolution, and pseudoephedrine supply-chain controls.

Blend uniformity and low-dose loratadine

The 5 mg loratadine dose creates a content-uniformity challenge. Direct compression may be viable if the active ingredient has suitable flow and particle-size properties. Otherwise, ordered mixing or wet granulation may be required.

High-dose pseudoephedrine processing

Pseudoephedrine sulfate accounts for a large share of tablet mass. The formulation must maintain:

• Consistent granule density.
• Low segregation risk.
• Adequate tablet hardness.
• Controlled friability.
• Uniform release across commercial batches.

Moisture management

Moisture can affect powder flow, tablet hardness, polymer hydration, and coating performance. Packaging should be assessed as part of the formulation rather than treated as a separate downstream decision. High-barrier blister packaging may improve stability and dose integrity but can raise unit costs compared with bottles.

Alcohol dose-dumping evaluation

Modified-release pseudoephedrine formulations require alcohol-interaction testing. A formulation that releases the dose too quickly in the presence of ethanol creates a regulatory and commercial risk. The polymer system, tablet porosity, coating, and excipient grade must be assessed together.

Pseudoephedrine controls

Pseudoephedrine products are subject to federal retail-purchase restrictions, sales-record requirements, quantity limits, and state-level controls under the Combat Methamphetamine Epidemic Act of 2005.[5] These requirements affect forecasting, distributor qualification, inventory controls, and retail execution.

What formulation patents protect loratadine and pseudoephedrine sulfate products?

The original chemical and product-specific patent position for the leading loratadine and pseudoephedrine combination is mature. The principal commercial protection now comes from formulation execution, trademarks, regulatory compliance, and distribution rather than broad composition-of-matter exclusivity.

Potentially relevant patent categories include:

• Extended-release matrix systems.
• Bilayer tablets separating immediate-release loratadine from controlled-release pseudoephedrine.
• Coated pseudoephedrine particles or pellets.
• Once-daily release profiles.
• Alcohol-resistant or abuse-deterrent release systems.
• Pediatric dosage forms.
• Taste-masked liquid or orally disintegrating products.
• Packaging systems that control moisture or prevent tampering.

Current patent assessment should distinguish between expired originator patents, live formulation patents, and patents that have no practical blocking effect because the commercial product can be designed around them. For an OTC product, a patent does not replace the need to confirm FDA monograph compliance and applicable labeling requirements.

What is the Orange Book status of loratadine and pseudoephedrine sulfate?

The Orange Book is principally a listing of approved prescription and certain other drug products with therapeutic-equivalence information. OTC monograph products generally do not have the same Orange Book framework as prescription new drug applications.

As a result, a prospective manufacturer should not assume that an Orange Book patent listing provides the complete exclusivity analysis for loratadine and pseudoephedrine sulfate. The relevant review should include:

• FDA monograph status.
• Any approved NDA or ANDA associated with the target product.
• Current FDA labeling.
• U.S. Patent and Trademark Office records.
• Patent litigation records.
• State and federal pseudoephedrine controls.
• Trademark and trade-dress restrictions.

When does loratadine and pseudoephedrine sulfate lose exclusivity?

The core market has already lost broad exclusivity. Loratadine was commercialized in the United States decades ago, and pseudoephedrine has an older generic history. Claritin-D products therefore compete in a mature market with generic and store-brand alternatives.

The commercial barriers are not conventional patent expiration dates. They are:

• FDA-compliant formulation development.
• Demonstration of equivalent release performance where an ANDA pathway applies.
• OTC monograph compliance.
• Trademark clearance.
• Retail listing and shelf placement.
• Pseudoephedrine distribution controls.
• Reliable supply of qualified active ingredients and excipients.

A sponsor seeking a differentiated product may create a new exclusivity position through an approved NDA, a novel delivery system, or a protected formulation. That position would depend on the specific regulatory pathway and patent claims and should not be inferred from the age of the active ingredients.

Are Paragraph IV challenges relevant to this product?

Paragraph IV litigation is less central for a conventional OTC monograph product than for a prescription product with listed patents in the Orange Book. A Paragraph IV certification becomes relevant if a manufacturer seeks approval through an ANDA referencing an approved product with listed patents.

For a monograph-compliant OTC product, the more likely entry routes are:

1. Direct marketing under the OTC monograph.
2. NDA or supplemental NDA development for a differentiated product.
3. Private-label manufacturing using an established compliant formulation.
4. An ANDA pathway where an applicable approved reference product and listed patents exist.

The legal risk is therefore product-specific. A company should review both FDA approval records and the patent family covering the exact dosage form, release profile, and manufacturing method.

Which companies are challenging the leading products?

The competitive field includes:

• National branded manufacturers.
• Store-brand and private-label OTC companies.
• Contract development and manufacturing organizations.
• Regional pharmacy suppliers.
• International manufacturers adapting the product for local markets.

The most direct competitors are generic or private-label versions of loratadine/pseudoephedrine extended-release tablets. In the United States, competition is constrained by pseudoephedrine retail controls and by the requirement that retailers manage regulated sales. In markets outside the United States, pseudoephedrine may be restricted, prescription-only, or replaced by another decongestant.

What commercial opportunities exist for excipient innovation?

Lower-cost 24-hour tablets

A robust hypromellose matrix with standard compression excipients can support a low-cost private-label product. The main opportunity is reducing manufacturing variability while preserving the reference dissolution profile.

Improved swallowability

Large pseudoephedrine tablets can create a patient-acceptance problem. Thin bilayer tablets, capsule-shaped tooling, film-coating optimization, and lower-friction surfaces can improve handling and swallowing without changing the active dose.

Abuse-resistant designs

Pseudoephedrine is subject to diversion controls because of its use in illicit methamphetamine production. Abuse-resistant packaging, unit-dose blistering, purchase monitoring, and tamper-evident systems can improve retailer acceptance. A formulation that limits dose dumping may offer a stronger regulatory and commercial position than a conventional matrix.

Pediatric and adolescent formats

A pediatric opportunity exists in age-appropriate dosage forms, but pseudoephedrine exposure, dosing accuracy, and labeling require careful evaluation. A liquid combination creates stability, palatability, preservative, and dose-measurement challenges. A multiparticulate sachet may provide better dose flexibility than a high-load tablet.

Reduced-excipient and allergen-positioned products

Some consumers seek products without lactose, artificial colors, or particular excipients. A color-free, lactose-free, or simplified formulation can support private-label differentiation, although excipient removal must not compromise dissolution or tablet robustness.

International reformulation

In jurisdictions where pseudoephedrine is unavailable or tightly controlled, the same excipient platform may be adapted to a different decongestant. That creates a formulation-development opportunity but does not produce a direct regulatory substitute for the U.S. product.

How does loratadine and pseudoephedrine sulfate compare with competing allergy products?

Product	Antihistamine	Decongestant	Main dosage-form opportunity	Commercial position
Loratadine/pseudoephedrine	Loratadine	Pseudoephedrine	12- or 24-hour extended-release tablet	Strong congestion-plus-allergy proposition
Cetirizine/pseudoephedrine	Cetirizine	Pseudoephedrine	Extended-release tablet	Competes on antihistamine brand preference
Fexofenadine/pseudoephedrine	Fexofenadine	Pseudoephedrine	Extended-release tablet	Higher-value positioning in some markets
Loratadine alone	Loratadine	None	Immediate-release tablet, chewable, liquid	Lower regulatory and manufacturing complexity
Intranasal steroid plus oral antihistamine	Variable	Usually none	Separate or combination delivery	Stronger local nasal treatment but different use case

The combination product has a clear benefit when congestion is a primary symptom. Loratadine alone is easier to manufacture, easier to distribute, and less subject to pseudoephedrine controls. The combination therefore needs either a meaningful symptom advantage, a competitive price, or superior convenience.

What regulatory status and FDA requirements apply?

FDA requirements depend on the proposed route to market. Key considerations include:

• Active ingredients and indications must comply with the applicable OTC monograph or approved application.
• Labeling must contain required warnings, directions, age restrictions, and contraindications.
• Extended-release performance must be supported by dissolution and stability data.
• Manufacturing must comply with current good manufacturing practice requirements.
• Pseudoephedrine distribution must comply with federal and state sales restrictions.
• Any new excipient use, unusual delivery system, or novel release mechanism may require additional FDA review.

The FDA’s OTC monograph system was substantially revised by the CARES Act, which replaced parts of the prior monograph rulemaking structure with an administrative order process.[2] Sponsors should evaluate the current monograph conditions rather than rely on historical monograph assumptions.

What generic launch risks exist for loratadine and pseudoephedrine sulfate?

A generic or private-label launch has five principal risks:

1. Release-profile failure. A formulation can pass assay and content uniformity while failing comparative dissolution.
2. Packaging noncompliance. Pseudoephedrine controls can disrupt sales even when the product is technically approved.
3. Supply interruption. Qualified pseudoephedrine sulfate and controlled-release polymers require dual-source planning.
4. Retail friction. Products sold behind the pharmacy counter or through restricted systems have lower impulse-purchase potential.
5. Seasonal demand volatility. Allergy-season demand can create inventory imbalance, discounting, and manufacturing pressure.

A launch plan should prioritize validated release performance and distribution execution over minor tablet-appearance differences.

What is the revenue exposure and market outlook?

Revenue is driven by seasonal allergy demand, congestion prevalence, retailer access, and the price gap between national brands and private-label products. The mature product category offers limited protection from direct generic substitution but supports recurring demand because consumers recognize the loratadine-pseudoephedrine combination as a specific congestion solution.

The most defensible commercial positions are:

• Low-cost private label with reliable supply.
• Premium 24-hour extended-release product.
• Easier-to-swallow tablet.
• Tamper-evident or abuse-resistant package.
• Pediatric or age-specific format where permitted.
• International adaptation using a locally permitted decongestant.

A conventional copy of an established tablet has limited pricing power. A differentiated formulation must show measurable value in release control, convenience, packaging, or patient usability.

How strong is the patent estate for loratadine and pseudoephedrine sulfate?

The base active-ingredient patent estate is weak because of product maturity and widespread generic availability. The formulation estate is more variable.

Protection category	Relative strength
Loratadine composition of matter	Low due to maturity
Pseudoephedrine sulfate composition of matter	Low due to maturity
Conventional extended-release matrix	Low to moderate, depending on claim scope and expiration
Bilayer tablet architecture	Moderate if claims are narrow and technically specific
Multiparticulate or coated-particle system	Moderate to strong if performance and structure are difficult to design around
Abuse-resistant release or packaging	Variable and highly claim-dependent
Trademark and trade dress	Potentially meaningful for branded products
Manufacturing know-how	Moderate, particularly for scale-up and dissolution consistency

Patent strength should be assessed claim by claim. A formulation patent covering only a particular polymer percentage or tablet geometry may have limited blocking value if a competing sponsor can use a different matrix, coating, or dosage-form architecture.

Key Takeaways

• Loratadine/pseudoephedrine sulfate is a mature OTC combination with limited base-drug exclusivity.
• The strongest formulation strategy is usually a bilayer tablet separating immediate-release loratadine from extended-release pseudoephedrine.
• Hypromellose matrix systems offer the best cost-performance balance for 12-hour and 24-hour products.
• Multiparticulates and osmotic systems provide differentiation but carry higher manufacturing and regulatory costs.
• Commercial opportunities include private label, improved swallowability, moisture-protective packaging, abuse-resistant designs, and age-appropriate formats.
• Orange Book and Paragraph IV analysis may be less central than OTC monograph compliance, FDA records, and product-specific patent review.
• Pseudoephedrine retail controls are a major commercial constraint.
• Patent strength is concentrated in narrow formulation, release, packaging, and manufacturing claims rather than active-ingredient claims.

FAQs

Can loratadine and pseudoephedrine sulfate be formulated as a liquid?

Yes, but the formulation is more difficult than a tablet because of loratadine’s limited water solubility, pseudoephedrine salt concentration, taste, preservative requirements, and dosing accuracy. A suspension or multiparticulate liquid may be more practical than a fully dissolved solution.

Is a bilayer tablet required for Claritin-D-type products?

No. A bilayer architecture is commercially attractive because it separates immediate-release loratadine from controlled-release pseudoephedrine, but a monolithic matrix or multiparticulate system may also be developed.

Which excipient is most important for 24-hour pseudoephedrine release?

A high-viscosity controlled-release polymer, often hypromellose, is usually the central excipient. Its grade, concentration, particle size, hydration behavior, and interaction with diluents determine much of the release profile.

Does pseudoephedrine require abuse-deterrent formulation technology?

Federal law imposes sales and purchase controls, but it does not make a specific abuse-deterrent formulation mandatory for every product. Tamper-evident packaging, unit-dose formats, and controlled-release designs may still create commercial and risk-management value.

Are biosimilar risks relevant to loratadine and pseudoephedrine sulfate?

No. Loratadine and pseudoephedrine sulfate are small-molecule drugs, not biologics. Competition arises from generics, OTC monograph products, private-label products, and branded line extensions rather than biosimilars.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Claritin-D 12 hour and Claritin-D 24 hour product labeling. National Library of Medicine.

2. U.S. Food and Drug Administration. (2023). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs

3. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

4. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products. Center for Drug Evaluation and Research.

5. U.S. Congress. (2005). Combat Methamphetamine Epidemic Act of 2005, Pub. L. No. 109-177, Title VII.